TY - JOUR
T1 - Probucol-poly(meth)acrylate-bile acid nanoparticles increase IL-10, and primary bile acids in prediabetic mice
AU - Mooranian, Armin
AU - Zamani, Nassim
AU - Takechi, Ryu
AU - Al-Sallami, Hesham
AU - Mikov, Momir
AU - Goločorbin-Kon, Svetlana
AU - Kovacevic, Bozica
AU - Arfuso, Frank
AU - Al-Salami, Hani
N1 - Funding Information:
The work is partially supported by the European Union Horizon 2020 MEDLEM research project and innovation program under the Marie Skl-odowska-Curie Grant Agreement no. 690876. H Al-Salami has been and is currently receiving funding from Beijing Nat-Med Biotechnology Co. Ltd. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Publisher Copyright:
© 2019 Newlands Press.
PY - 2019
Y1 - 2019
N2 - Aim: Common features in insulin-resistance diabetes include inflammation and liver damage due to bile acid accumulation. Results & methodology: This study aimed to test in vivo pharmacological effects of combining two drugs, ursodeoxycholic acid that has bile acid regulatory effects, and probucol (PB) that has potent anti-oxidative stress effects, using a new poly(meth)acrylate nano-targeting formulation on prediabetic mice. Mice were made diabetic and were fed daily with either PB, nanoencapsulated PB or nanoencapsulated PB-ursodeoxycholic acid before blood, tissues, urine and feces were collected for inflammation and bile acid measurements. The nanoencapsulated PB-ursodeoxycholic acid formulation increased plasma IL-10, and increased the concentration of primary bile acids in the liver and heart. Conclusion: Results suggest potential applications in regulating IL-10 in insulin-resistance prediabetes.
AB - Aim: Common features in insulin-resistance diabetes include inflammation and liver damage due to bile acid accumulation. Results & methodology: This study aimed to test in vivo pharmacological effects of combining two drugs, ursodeoxycholic acid that has bile acid regulatory effects, and probucol (PB) that has potent anti-oxidative stress effects, using a new poly(meth)acrylate nano-targeting formulation on prediabetic mice. Mice were made diabetic and were fed daily with either PB, nanoencapsulated PB or nanoencapsulated PB-ursodeoxycholic acid before blood, tissues, urine and feces were collected for inflammation and bile acid measurements. The nanoencapsulated PB-ursodeoxycholic acid formulation increased plasma IL-10, and increased the concentration of primary bile acids in the liver and heart. Conclusion: Results suggest potential applications in regulating IL-10 in insulin-resistance prediabetes.
KW - insulin-resistance diabetes
KW - nanoencapsulation
KW - poly(meth)acrylate
KW - primary bile acid
KW - probucol
UR - http://www.scopus.com/inward/record.url?scp=85074527921&partnerID=8YFLogxK
U2 - 10.4155/tde-2019-0052
DO - 10.4155/tde-2019-0052
M3 - Article
C2 - 31646943
AN - SCOPUS:85074527921
SN - 2041-5990
VL - 10
SP - 563
EP - 571
JO - Therapeutic Delivery
JF - Therapeutic Delivery
IS - 9
ER -
